Isolated limb infusion chemotherapy for melanoma: An overview of early experience at the Adelaide Melanoma Unit

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 243-249

  Giles, Mitchell H ^a   Coventry, Brendon J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Actinomycin D; Intra arterial infusion; Melphalan; Metastatic melanoma; Regional therapy

Indexed keywords

CREATINE KINASE; DACTINOMYCIN; MELPHALAN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CREATINE KINASE BLOOD LEVEL; DEBRIDEMENT; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE CELLULITIS; ISOLATED LIMB INFUSION CHEMOTHERAPY; LIMB AMPUTATION; LIMB DISEASE; MALE; MEDICAL PARAMETERS; MELANOMA; RECURRENT CANCER; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84882654543     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S45746     Document Type: Article

References (34)

1. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries 2012. Cancer in Australia: an overview, 2012. Australian Cancer Incidence and Mortality Workbooks Melanoma. Cancer series no 74. Catalog number CAN 70. Canberra, Australia: Australian Institute of Health and Welfare; 2012.
2. Francken AB, Accortt NA, Shaw HM, etal. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15:1476-1484.
3. Creech O Jr, Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by isolated perfusion. Cancer Chemother Rep. 1962;16: 579-581.
4. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol. 2007;14:230-238.
5. Knorr C, Meyer T, Janssen T, etal. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol. 2006;32:224-227.
6. Noorda EM, Vrouenraets BC, Nieweg OE, Kroon BB. Isolated limb perfusion in regional melanoma. Surg Oncol Clin N Am. 2006;15: 373-384.
7. Takkenberg RB, Vrouenraets BC, van Geel AN, etal. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol. 2005;91:107-111.
8. Aloia TA, Grubbs E, Onaitis M, etal. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg. 2005;140:1115-1120.
9. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903-907.
10. Reintgen M, Reintgen C, Nobo C, Giuliano Shivers RS, Reintgen D. Regional therapy for recurrent metastatic melanoma confined to the extremity: hyperthermic isolated limb perfusion vs isolated limb infusion. Cancers. 2012;2:43-50.
11. Deroose JP, Eggermont AM, van Geel AN, Verhoef C. Isolated limb perfusion for melanomain-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol. 2011;23:183-188.
12. Testori A, Verhoef C, Kroon HM, et al. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol. 2011;104:397-404.
13. Vrouenraets BC, Kroon BB, Nieweg OE, Thompson JF. Isolated limb perfusion for melanoma: results and complication. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of Melanoma. London, UK: Martin Dunitz; 2004.
14. Koops HS, Vaglini M, Suciu S, etal. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organiation Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16:2906-2912.
15. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-247.
16. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127-136.
17. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003-3013.
18. Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol. 2009;100:169-177.
19. Wieberdink J, Benckhuysen C, Braat RP, etal. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18: 905-910.
20. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
21. Balch CM, Buzaid AC, Soong SJ, etal. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
22. Testori A, Faries MB, Thompson JF, etal. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104:391-396.
23. Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J. 2012;18:203-207.
24. Chapman PB, Hauschild A, Robert C, etal. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
25. Sosman JA, Kim KB, Schuchter L, etal. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
26. Beasley GM, Caudle A, Petersen RP, etal. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706-715.
27. Duprat Neto JP, Mauro AC, Molina AS, etal. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity. ANZ J Surg. September 24, 2012. [Epub ahead of print.]
28. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932-1940.
29. Lassau N, Chami L, Chebil M, etal. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011;11:18-24.
30. Coventry BJ, Ashdown ML. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 2012;4:137-149.
31. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res. 2008;18: 405-411.
32. Foote MC, Burmeister BH, Thomas J, Mark Smithers B. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res. 2010;20:48-51.
33. Shafren DR, Au GG, Nguyen T, etal. Systemic therapy of malignant human melanoma tumors by a common cold-producing virus, coxsackievirus A21. Clin Cancer Res. 2004;10:53-60.
34. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australasian Journal of Dermatology. 2009;50:266-271.